Cytosorbents Crp (NASDAQ:CTSO) — Market Cap & Net Worth
Market Cap & Net Worth: Cytosorbents Crp (CTSO)
Cytosorbents Crp (NASDAQ:CTSO) has a market capitalization of $18.06 Million ($18.06 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #25534 globally and #5383 in its home market, demonstrating a -16.35% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cytosorbents Crp's stock price $5.73 by its total outstanding shares 3151101 (3.15 Million). Also see Cytosorbents Crp balance sheet assets for a full breakdown of the balance sheet.
Cytosorbents Crp Market Cap History: 2015 to 2026
Cytosorbents Crp's market capitalization history from 2015 to 2026. Data shows change from $17.55 Million to $18.06 Million (-0.82% CAGR). Also see cash flow conversion of Cytosorbents Crp for how efficiently the company converts equity into cash flow.
Index Memberships
Cytosorbents Crp is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.00% | #722 of 976 |
|
NASDAQ Composite
IXIC
|
$41.69 Trillion | 0.00% | #2360 of 3165 |
Weight: Cytosorbents Crp's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Cytosorbents Crp Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cytosorbents Crp's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Cytosorbents Crp share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.05x
Cytosorbents Crp's market cap is 0.05 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $17.17 Million | $8.21 Million | -$11.94 Million | 2.09x | N/A |
| 2017 | $20.48 Million | $13.38 Million | -$8.46 Million | 1.53x | N/A |
| 2018 | $25.46 Million | $20.25 Million | -$17.21 Million | 1.26x | N/A |
| 2019 | $12.13 Million | $22.77 Million | -$19.27 Million | 0.53x | N/A |
| 2020 | $25.11 Million | $39.45 Million | -$7.84 Million | 0.64x | N/A |
| 2021 | $13.20 Million | $40.11 Million | -$24.56 Million | 0.33x | N/A |
| 2022 | $4.88 Million | $34.69 Million | -$32.81 Million | 0.14x | N/A |
| 2023 | $3.50 Million | $31.08 Million | -$29.25 Million | 0.11x | N/A |
| 2024 | $2.87 Million | $35.59 Million | -$20.72 Million | 0.08x | N/A |
| 2025 | $2.01 Million | $37.06 Million | -$8.20 Million | 0.05x | N/A |
Competitor Companies of CTSO by Market Capitalization
Companies near Cytosorbents Crp in the global market cap rankings as of September 18, 2026. Review CTSO tangible net assets ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Cytosorbents Crp by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #125 globally with a market cap of $177.99 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #228 globally with a market cap of $109.30 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #229 globally with a market cap of $109.23 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #239 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #125 | Abbott Laboratories | NYSE:ABT | $177.99 Billion | $102.36 |
| #228 | Medtronic PLC | NYSE:MDT | $109.30 Billion | $92.60 |
| #229 | Stryker Corporation | NYSE:SYK | $109.23 Billion | $284.76 |
| #239 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
Cytosorbents Crp Historical Marketcap From 2015 to 2026
Between 2015 and today, Cytosorbents Crp's market cap moved from $17.55 Million to $ 18.06 Million, with a yearly change of -0.82%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $18.06 Million | +796.43% |
| 2025 | $2.01 Million | -29.76% |
| 2024 | $2.87 Million | -18.02% |
| 2023 | $3.50 Million | -28.39% |
| 2022 | $4.88 Million | -63.01% |
| 2021 | $13.20 Million | -47.43% |
| 2020 | $25.11 Million | +107.01% |
| 2019 | $12.13 Million | -52.35% |
| 2018 | $25.46 Million | +24.31% |
| 2017 | $20.48 Million | +19.27% |
| 2016 | $17.17 Million | -2.15% |
| 2015 | $17.55 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Cytosorbents Crp was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $18.06 Million USD |
| MoneyControl | $18.06 Million USD |
| MarketWatch | $18.06 Million USD |
| marketcap.company | $18.06 Million USD |
| Reuters | $18.06 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cytosorbents Crp
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and criti… Read more